Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: Histopathologic findings and clinical implications

Ophthalmology

Volumn 118, Issue 4, 2011, Pages 636-641

  El Sabagh, Hazem A ^a   Abdelghaffar, Walid ^d   Labib, Ahmad M ^b,c   Mateo, Carlos ^e   Hashem, Tarek M ^f,g   Al Tamimi, Dalal M ^f   Selim, Abdulhafez A ^h,i  

^a Magrabi Eye and Ear Center   (Saudi Arabia)

^b Magrabi Eye Hospital   (Egypt)

^c Magrabi Eye Center   (Yemen)

^d BENHA UNIVERSITY   (Egypt)

^e Ocular Microsurgery Institute   (Spain)

^f IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^g AIN SHAMS UNIVERSITY   (Egypt)

^h KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS   (Saudi Arabia)

ⁱ Osteotech Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CD34 ANTIGEN; COLLAGEN; SMOOTH MUSCLE ACTIN;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; DIABETES MELLITUS; DRUG USE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; OCULAR FIBROSIS; OPTICAL COHERENCE TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; VITRECTOMY;

ACTINS; ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD34; COLLAGEN; COMBINED MODALITY THERAPY; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RETINAL NEOVASCULARIZATION; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITRECTOMY; YOUNG ADULT;

EID: 79953294302     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.08.038     Document Type: Article

References (21)

1. Olk RJ, Lee CM. Classification of Diabetic Retinopathy. In: Olk RJ, Lee CM, eds. Diabetic Retinopathy: Practical Management. Philadelphia, PA: Lippincott; 1993:14-8.
2. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in diabetic population. Ophthalmology 1998;105:998-1003. (Pubitemid 28268322)
3. Fong DS, Ferris FL III, Davis MD, Chew EY, Early Treatment Diabetic Retinopathy Study Research Group. Causes of severe visual loss in the Early Treatment Diabetic Retinopathy Study: ETDRS report no. 24. Am J Ophthalmol 1999;127:137-41. (Pubitemid 29072552)
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29. (Pubitemid 36207453)
5. Hinton DR, He S, Jin ML, et al. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond) 2002;16:422-8. (Pubitemid 34845970)
6. He S, Jin ML, Worpel V, Hinton DR. A role for connective tissue growth factor in the pathogenesis of choroidal neovascularization. Arch Ophthalmol 2003;121:1283-8. (Pubitemid 37128406)
7. Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 2006;124:1457-62. (Pubitemid 44537147)
8. Hinton DR, Spee C, He S, et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 2004;27:758-64. (Pubitemid 38280546)
9. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One [serial online] 2008;3:e2675. Available at: http://www.plosone.org/article/ info%3Adoi%2F10.1371%2Fjournal.pone.0002675. Accessed July 5, 2010.
10. Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8.
11. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorhhage. Retina 2006;26:275-8. (Pubitemid 44318179)
12. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-1705.
13. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina 2006;26:699-700.
14. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol 2008;92:213-6. (Pubitemid 351224097)
15. Wu L, Martinez-Castellanos MA, Quirroz-Mercado H, et al, Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injection of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7.
16. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7. (Pubitemid 24356306)
17. Lüttke B, Lang GE, Böhm BO, Lang GK. Results of panretinal argon laser coagulation in proliferative diabetic retinopathy [in German]. Ophthalmologe 1996;93:694-8. (Pubitemid 27046902)
18. Tinley CG, Gray RH. Routine, single session, indirect laser for proliferative diabetic retinopathy. Eye (Lond) 2009;23:1819-23.
19. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004;7:335-45. (Pubitemid 40767935)
20. Zhu Q, Ziemssen F, Henke-Fahle S, et al, Tübingen Bevacizumab Study Group. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008;115:1750-5.
21. Jorge R, Costa RA, Calucci D, et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina 2006;26:1006-13.